Literature DB >> 1719016

Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study.

A Gray1, H A Feldman, J B McKinlay, C Longcope.   

Abstract

To evaluate the hypothesis that endocrine profiles change with aging independently of specific disease states, we examined the age trends of 17 major sex hormones, metabolites, and related serum proteins in 2 large groups of adult males drawn from the Massachusetts Male Aging Study, a population-based cross-sectional survey of men aged 39-70 yr conducted in 1986-89. Group 1 consisted of 415 men who were free of obesity, alcoholism, all prescription medication, prostate problems, and chronic illness (cancer, coronary heart disease, hypertension, diabetes, and ulcer). Group 2 consisted of 1294 men who reported 1 or more of the above conditions. Each age trend was satisfactorily described by a constant percent change per yr between ages 39-70 yr. Free testosterone declined by 1.2%/yr, and albumin-bound testosterone by 1.0%/yr. Sex hormone-binding globulin (SHBG), the major serum carrier of testosterone, increased by 1.2%/yr, with the net effect that total serum testosterone declined more slowly (0.4%/yr) than the free or albumin-bound pools alone. Among the major androgens and metabolites, androstane-3 alpha,17 beta-diol (androstanediol; 0.8%/yr) and androstanediol glucuronide (0.6%/yr) declined less rapidly than free testosterone, while 5 alpha-dihydrotestosterone remained essentially constant between ages 39-70 yr. Androstenedione declined at 1.3%/yr, a rate comparable to that of free testosterone, while the adrenal androgen dehydroepiandrosterone (3.1%/yr) and its sulfate (2.2%/yr) declined 2-3 times more rapidly. The levels of testosterone, SHBG, and several androgen metabolites followed a parallel course in groups 1 and 2, remaining consistently 10-15% lower in group 2 across the age range of the study. Subgroup analyses suggested that obese subjects might be responsible for much of the group difference in androgen level. Serum concentrations of estrogens and cortisol did not change significantly with age or differ between groups. Of the pituitary gonadotropins, FSH increased at 1.9%/yr, LH increased at 1.3%/yr, and PRL declined at 0.4%/yr, with no significant difference between groups 1 and 2.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719016     DOI: 10.1210/jcem-73-5-1016

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  155 in total

Review 1.  Muscle strength testing: use of normalisation for body size.

Authors:  Slobodan Jaric
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  [Dermatoendocrinology. Skin aging].

Authors:  E Makrantonaki; C C Zouboulis
Journal:  Hautarzt       Date:  2010-06       Impact factor: 0.751

4.  Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors.

Authors:  Claudia Bighin; Gianluigi Lunardi; Lucia Del Mastro; Paola Marroni; Paola Taveggia; Alessia Levaggi; Sara Giraudi; Paolo Pronzato
Journal:  Oncologist       Date:  2010-12-08

5.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Authors:  Eduard García-Cruz; Jorge Huguet; Marta Piqueras; Meritxell Pérez Márquez; Lluís Peri; Laura Izquierdo; Agustín Franco; Ricardo Alvarez-Vijande; María José Ribal; Antonio Alcaraz
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

6.  Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study.

Authors:  R Haring; V Xanthakis; A Coviello; L Sullivan; S Bhasin; H Wallaschofski; J M Murabito; R S Vasan
Journal:  Int J Androl       Date:  2012-05-29

Review 7.  The evaluation and management of testosterone deficiency: the new frontier in urology and men's health.

Authors:  William P Conners; Abraham Morgentaler
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

8.  Serum total testosterone level and identification of late-onset hypogonadism: a community-based study.

Authors:  Sungmin Kang; Hyun Jun Park; Nam Cheol Park
Journal:  Korean J Urol       Date:  2013-09-10

Review 9.  Depression in aging men: the role of testosterone.

Authors:  Ryan M Carnahan; Paul J Perry
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Age-related prevalence of low testosterone in men with spinal cord injury.

Authors:  William A Bauman; Michael F La Fountaine; Ann M Spungen
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.